Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TGM2 | P21980 | 2/20 | 0.31 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.30 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL733227 | 1.00 | ALDH1A1 (0.34) | ALDH1A1L3MBTL1HRH4HRH3LMNA | |
| SCHEMBL731552 | 0.85 | ALDH1A1 (0.35) | ALDH1A1L3MBTL1HRH4HRH3LMNA | |
| SCHEMBL1988212 | 0.85 | ALDH1A1 (0.35) | ALDH1A1L3MBTL1HRH4HRH3LMNA | |
| SCHEMBL1984791 | 0.81 | LMNA (0.37) | ALDH1A1HRH3LMNAABCC4MAPT | |
| SCHEMBL731304 | 0.81 | LMNA (0.37) | ALDH1A1HRH3LMNAABCC4MAPT | |
| SCHEMBL731050 | 0.80 | ALDH1A1 (0.40) | ALDH1A1LMNAABCC4MAPT | |
| SCHEMBL733660 | 0.80 | ALDH1A1 (0.40) | ALDH1A1LMNAABCC4MAPT | |
| SCHEMBL2043708 | 0.80 | ALDH1A1 (0.40) | ALDH1A1LMNAABCC4MAPT | |
| SCHEMBL2042688 | 0.80 | ALDH1A1 (0.40) | ALDH1A1LMNAABCC4MAPT | |
| SCHEMBL8250067 | 0.78 | ALDH1A1 (0.39) | ALDH1A1L3MBTL1HRH4HRH3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2079479-B1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2014-11-26 | — | — | EP | disclosed |
| EP-1913016-B1 | MACROCYCLIC PEPTIDES AS HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2013-01-16 | — | — | EP | disclosed |
| US-8278322-B2 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-10-02 | — | — | US | disclosed |
| US-8138164-B2 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20110028494-A1 | HCV NS3 Protease Inhibitors | MERCK SHARP & DOHME LLC | 2011-02-03 | — | — | US | disclosed |
| US-20100317623-A1 | HCV NS3 Protease Inhibitors | MERCK SHARP & DOHME LLC | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317623-A1 | HCV NS3 Protease Inhibitors | HAVCR2, GTF3C3, CTSC | ALDH1A1 1199/4885L3MBTL1 2610/4885HRH4 4577/4885 |
| US-20110028494-A1 | HCV NS3 Protease Inhibitors | HAVCR2, GTF3C3, CTSC | ALDH1A1 1199/4885L3MBTL1 2610/4885HRH4 4577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.